NEWS
Future PharmaTech 2025 Annual Shareholders Meeting Successfully Concluded
Thank you to all shareholders for your participation and support. Your valuable feedback and encouragement drive our continued progress. We remain committed to steady operations and innovation, striving to enhance company performance and create greater value for all shareholders.
D&B Enterprise Certification Cloud Badge Delivered
Future PharmaTech has successfully obtained the prestigious Dun & Bradstreet (D&B) enterprise certification, earning the coveted D-U-N-S®Registered™ cloud badge. This globally recognized credential significantly enhances our corporate credibility, validates our business legitimacy, and opens doors to international partnerships and opportunities.
Future PharmaTech Signs ED Drug Licensing Deal with PBF Group
The licensing agreement grants PBF exclusive rights in Taiwan and priority negotiation rights in Greater China for an innovative ED therapy. Developed via the 505(b)(2) pathway, this accelerates entry into the men's health and urology specialty markets.
Future PharmaTech's Two Lead Drug Candidates Set to Enter Phase II Trials
Focusing on vascular dementia and ED treatment, two promising compounds are set to enter Phase II clinical trials next year with strong global market potential. Both innovative drug development programs are progressing smoothly, demonstrating strong market competitiveness.
Prof. Chao Ming-Wei Leads R&D Strategy – Dementia Drug Poised for Clinical Entry
Prof. Chao Ming-Wei, an expert in toxicology, serves as advisor to Future PharmaTech's innovative dementia treatment program. The vascular dementia drug is expected to begin clinical trials next year, bringing new hope to Alzheimer's patients.
